Amyotrophic Lateral Sclerosis (ALS)MNDNCT07187388
Investigating the Impact of Electrical Stimulation on Facial Pain, Jaw Movement and Oral Health in People With Motor Neuron Disease.
A study testing Transcutaneous Electrical Nerve Stimulation to reduce facial pain and improve jaw range of motion in ALS and PLS in people with Amyotrophic Lateral Sclerosis (ALS) and Primary Lateral Sclerosis (PLS), run by Nova Southeastern University at 1 site in United States.
Trial summary
The goal of this clinical trial is to evaluate the impact of non-invasive electrical stimulation, when placed on the facial muscles can reduce facial pain and improve jaw mobility, and chewing in individuals with Amyotrophic Lateral Sclerosis (ALS) and Primary Lateral Sclerosis (PLS). Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Amyotrophic Lateral Sclerosis (ALS), Primary Lateral Sclerosis (PLS), Motor Neuron Disease, Amyotrophic Lateral Sclerosis
- What is being tested?
- Transcutaneous Electrical Nerve Stimulation to reduce facial pain and improve jaw range of motion in ALS and PLS
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 10 participants
- Where
- 1 siteUnited States
- Study dates
- 2 Apr 2026to 13 Aug 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Diagnosis of possible, probable, or definite ALS (El-Escorial Revisited) OR diagnosis of definite PLS by the treating neurologist and based on the consensus diagnostic criteria for PLS
- Subjective report of jaw pain, indicated by a NRS score of > or = 3/10.
Who cannot join
- history of head or neck cancer
- history of CVA
- history of past facial surgery with hardware placement
- history of pacemaker
- diagnosis of significant cognitive impairment by the treating physician
- history of seizures or diagnosis of epilepsy
- open wound at the area of electrode placement
- complete loss of sensation at the area of electrode placement
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
Nova Southeastern University, David and Cathy Husman Neuroscience Institute
Davie, Florida, 33314
Kayla Chomko, PT, DPT, 954-817-5730, kayla.chomko@nova.edu
Raquel Garcia, SLP.D, CCC-SLP, BCS-S, 954-914-5447, rw602@nova.edu
About this study
Official title: The Impact of Transcutaneous Electrical Stimulation on Facial Pain, Jaw Mobility, and Oral Health in Individuals With Motor Neuron Disease.
The goal of this clinical trial is to evaluate the impact of non-invasive electrical stimulation, when placed on the facial muscles can reduce facial pain and improve jaw mobility, and chewing in individuals with Amyotrophic Lateral Sclerosis (ALS) and Primary Lateral Sclerosis (PLS). The secondary goal is to evaluate the impact of non-invasive electrical stimulation on patient reported difficulty performing oral hygiene tasks in individuals with ALS and PLS. Participants will attend one in-person clinic visit and participate in one telephone interview 24 hours after the treatment. The clinic visit will include pre-intervention assessments, a single 30-minute treatment of electrical stimulation followed by post-intervention assessments.
The assessments will include a self-rating of jaw and facial pain, a range of motion test where participants will be asked to open their jaw as wide and as far to the side as possible, and a chewing efficiency test using a saltine cracker. Twenty-four hours later, participants will receive a follow-up phone call to self-rate their facial pain and report any difficulty performing oral hygiene tasks.
The treatment consists of a single 30-minute electrical stimulation session. Electrode pads will be placed on the participant's facial region, specifically over the masseter muscle belly and the TMJ area, while the participant is seated comfortably. The pads will be connected to an FDA-approved electrical stimulator, and the current will be adjusted to the participant's comfort level. Once set, the participant will remain seated for 30 minutes. At the end of the session, the stimulator will be turned off and the electrode pads removed.
Read the detailed description
In this prospective, cross-sectional study, individuals with ALS and PLS will participate in one in-person clinic visit, followed by a telephone interview 24 hours post-treatment. During the clinic visit, pre-intervention assessments will be conducted to evaluate facial pain, jaw range of motion (jROM), mastication efficiency, and patient-reported difficulty with oral hygiene tasks. Following these assessments, participants will receive a single 30-minute TENS treatment. The PI or Co-PI will be present throughout the intervention, monitoring for any discomfort and providing participants the option to discontinue treatment if needed using a predetermined signal.
Post-intervention assessments, identical to the pre-intervention evaluations, will then take place. The entire clinic visit is expected to take approximately 90 minutes. A brief telephone interview 24 hours after the intervention will collect subjective feedback, including patient-reported pain levels and perceived difficulty of performing oral hygiene tasks.
The primary outcome measure will be patient-reported pain, defined by the International Association for the Study of Pain "an unpleasant sensory and emotional experience associated with, or resembling that associated with, actual or potential tissue damage," localized to the jaw region and assessed using a Numeric Rating Scale (NRS). Secondary outcome measures will include jROM, the ability to chew solid foods, and participants' perceived difficulty with oral hygiene tasks, as outlined below.
Participants.
Participants will be identified and recruited during weekly ALS/PLS multidisciplinary clinic visits. The study will enroll 10 pALS/pPLS between the ages of 25 and 90.
METHODS Pre-Intervention Assessment: Estimated Time 25 minutes
- Jaw Pain Assessment: Pain levels will be assessed using the NRS scale. This scale uses a 0-10 numeric range, where 0 represents no pain and 10 represents the worst possible pain. Participants will rate their pain by choosing a number between 0 and 10 to indicate their pain intensity pre-, post-, and 24 hours post-intervention.
- Jaw Range of Motion Assessment To measure maximal incisal opening (oral opening), the TheraBite range of motion (ROM) scale will be used. The TheraBite ROM scale is a disposable tool that assists investigators to assess the distance in millimeters (mm) between the upper and lower central incisors when the patient opens their mouth as wide as possible or performs lateral jaw movements. Maximum interincisal distance (MID) and Maximal lateral jaw movement will be measured in mm both pre- and post- intervention. The participant will be instructed to open their mouth as wide as possible within a pain-free range. The TheraBite ROM Scale will be positioned between the upper and lower central incisors, and the maximum opening will be measured in millimeters (mm). The participant will be instructed to move their jaw sideways to the left and right within a pain-free range. The TheraBite ROM Scale will be used to measure the distance between the midline of the upper and lower teeth, with the values recorded in millimeters (mm). A surface EMG sensor will be positioned on the masseter muscle belly during both jROM assessments to measure muscle activity at rest, during passive stretch and during muscle activation. This will provide real-time data visualization to quantify muscle activation patterns pre- and post- intervention.
- Mastication Efficiency Assessment : Test of Mastication and Swallowing Solids (TOMASS)
The TOMASS will be utilized to assess solid bolus ingestion by quantifying masticatory efficiency, speed, and safety, providing objective measurements of mastication performance. The objective outcomes include the number of masticatory cycles and swallows per bite, and duration.
3b. Oral Transit Time (OTT)
In the event the participant cannot chew a saltine cracker, required for the TOMASS, the OTT will be utilized. The OTT is a tool to quantify how many seconds it takes a participant to consume a modified textured food item (IDDSI level 4, apple sauce) and clear bolus from oral cavity. OTT will be described using quantitative parameters from the Mann Assessment of Swallowing Ability (MASA): Score of 2 = No oral transit movement observed; Score of 4 = delay >10 seconds ; Score of 6 =delay > 5 seconds; Score of 8 = delay >1 second; Score of 10 = no OTT delay.
- Oral Hygiene - Numerical Rating Scale (NRS)
Patient-reported difficulty completing oral hygiene will be assessed using a NRS ranging from 0 (no difficulty) to 10 (significant difficulty). Participants will rate their perceived difficulty pre-intervention and 24 hours post intervention.
- TENS Intervention - 40 minutes
TENS intervention will be administered using a current-controlled TENS device that produces charge-balanced, symmetrical biphasic rectangular pulses. Participants will be seated and skin cleaned prior to applying 2 self-adhesive round surface electrodes (25mm) on each side of the face. One electrode (anode) will be placed over the masseter muscle belly, while the other (cathode) will be positioned over the TMJ. Electrode placement will be confirmed by palpation of the TMJ and Masseter. This set up will be mirrored on the opposite side. Once all 4 electrodes are in place, the TENS unit will be turned on. This is estimated to take 10 minutes.
Participants will remain seated. The TENS unit will be set to manual mode to deliver the stimulation at a frequency of 50 Hertz (Hz) and a pulse width of 200 microseconds (µseconds). Stimulation amplitudes will be gradually increased from 0 milliamps (mA) to each participant's tolerance level. Participants will be instructed to indicate when the stimulation feels "strong but comfortable." The tolerated mA level will be recorded and maintained for the full 30-minute session.
The PI or Co-PI will be present throughout the intervention, monitoring for any discomfort and providing participants the option to discontinue treatment if needed. At the end of the session, the TENS device will be powered off, electrodes will be removed, and post-intervention testing will be conducted.
- Post Intervention Assessments are identical to pre-intervention assessments and are estimated to take 25 minutes.
- 24 hour telephone interview - Estimated time - 10 minutes. The participant will be contacted 24 hours after completion of intervention and a telephone interview will be conducted. The PI or co-PI will contact the participant and collect subjective feedback, including patient reported pain levels, perceived difficulty of performing oral hygiene tasks, both rated utilizing the NRS.
- Conditions
- Amyotrophic Lateral Sclerosis (ALS), Primary Lateral Sclerosis (PLS), Motor Neuron Disease, Amyotrophic Lateral Sclerosis
- Being tested
- Transcutaneous Electrical Nerve Stimulation to reduce facial pain and improve jaw range of motion in ALS and PLS
- Keywords
- Amyotrophic Lateral Sclerosis, Primary Lateral Sclerosis, ALS, PLS, Motor Neuron Disease, MND, Facial Pain, jaw pain
- Medical subject headings
- Amyotrophic Lateral Sclerosis, Motor Neuron Disease, Facial Pain
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Transcutaneous Electrical Nerve Stimulation to reduce facial pain and improve jaw range of motion in ALS and PLSDevice
TENS intervention will be administered using a current-controlled TENS device that produces charge-balanced, symmetrical biphasic rectangular pulses. Participants will be seated and skin cleaned prior to applying 2 self-adhesive round surface electrodes (25mm) on each side of the face. One electrode (anode) will be placed over the masseter muscle belly, while the other (cathode) will be positioned over the TMJ. Electrode placement will be confirmed by palpation of the TMJ and Masseter. This set up will be mirrored on the opposite side. Once all 4 electrodes are in place, the TENS unit will be turned on.
Participants will remain seated. The TENS unit will be set to manual mode to deliver the stimulation at a frequency of 50 Hertz (Hz) and a pulse width of 200 microseconds (µseconds). Stimulation amplitudes will be gradually increased from 0 milliamps (mA) to each participant's tolerance level. The 30 minute TENS intervention will then take place.
| Study group | Role | What they receive |
|---|---|---|
| Transcutaneous electrical stimulation to reduce facial pain and improve jaw ROM in ALS and PLS. | Experimental | All 10 participants will receive a single TENS intervention, with electrodes placed over the masseter and TMJ regions. This intervention is designed to evaluate TENS as a potential treatment for reducing facial pain and improving jaw mobility and chewing function in individuals with ALS and PLS.. Receives: Device: Transcutaneous Electrical Nerve Stimulation to reduce facial pain and improve jaw range of motion in ALS and PLS |
What is being measured
The primary outcome is the main question the study is designed to answer.
Numerical Rating Scale for Pain
0-10 numeric rating scale where participants will self rate their pain on a scale of 0-10 with 0 = no pain and 10 = worst possible pain.
Measured: Baseline, immediately post-intervention and 24 hours post-intervention
Secondary outcomes (3)
Jaw Range of Motion (jROM) Assessment
Maximum interincisal distance (MID) and Maximal lateral jaw movement will be measured utilizing the TheraBite range of motion scale. The participant will be instructed to open their mouth as wide as possible within a pain-free range. The TheraBite ROM Scale will be positioned between the upper and lower central incisors, and the maximum opening will be measured in millimeters (mm). The participant will be instructed to move their jaw sideways to the left and right within a pain-free range. The TheraBite ROM Scale will be used to measure the distance between the midline of the upper and lower teeth, with the values recorded in millimeters (mm). A surface EMG sensor will be positioned on the masseter muscle belly during both jROM assessments to measure muscle activity at rest, during passive stretch and during muscle activation. This will provide real-time data visualization to quantify muscle activation patterns pre- and post- intervention.
Measured: Baseline and immediately post-intervention
Test of Mastication and Swallowing Solids (TOMASS)
The TOMASS will be utilized to assess solid bolus ingestion by quantifying masticatory efficiency, speed, and safety, providing objective measurements of mastication performance. The TOMASS allows clinicians to capture detailed information about the relationship between jaw function, pain, and mastication issues when consuming a standardized solid food item (saltine cracker). The objective outcomes include the number of masticatory cycles and swallows per bite, and duration.
Measured: Baseline and immediately post-intervention
Numeric Rating Scale for Oral Hygiene
Patient-reported difficulty completing oral hygiene will be assessed using a NRS ranging from 0 (no difficulty) to 10 (significant difficulty). Participants will rate their perceived difficulty by providing a number from 0 (no difficulty) to 10 (significant difficulty).
Measured: Baseline and 24 hours post intervention.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 Sep 2025
- Study start2 Apr 2026
- Primary completion13 Aug 2026 (estimated)
- Study completion13 Aug 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (3)Papers the sponsor has linked to this study.
- Other trials for Amyotrophic Lateral Sclerosis (ALS)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 10 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Nova Southeastern University
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07187388
- Sponsor's protocol ID
- 2025-356-NSU
- Acronym
- MND
- Status last verified
- May 2026
- First submitted
- 18 Sep 2025
- Last updated
- 27 May 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
- Individual data sharing
- Yes: All 10 participants baseline assessments, post assessments and 24 hour interview responses will be shared.
Publications
Alizadeh A, Karagah A, Tabrizi R, Shadman L, Arjmand A, Tofangchiha M, Patini R. Effect of transcutaneous electrical nerve stimulation on pain, edema, and trismus after surgical removal of impacted third molars: a split-mouth randomized clinical trial. Med Oral Patol Oral Cir Bucal. 2024 Mar 1;29(2):e211-e218. doi: 10.4317/medoral.26193.
PubMed 37823292Zayan K, Felix ER, Galor A. Transcutaneous Electrical Nerve Stimulation for Facial Pain. Prog Neurol Surg. 2020;35:35-44. doi: 10.1159/000509620. Epub 2020 Jul 21.
PubMed 32694253Shanavas M, Chatra L, Shenai P, Rao PK, Jagathish V, Kumar SP, Naduvakkattu B. Transcutaneous electrical nerve stimulation therapy: An adjuvant pain controlling modality in TMD patients - A clinical study. Dent Res J (Isfahan). 2014 Nov;11(6):676-9.
PubMed 25540662
Study at a glance
From the registry record, last updated by the sponsor on 27 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Impact of Transcutaneous Electrical Stimulation on Facial Pain, Jaw Mobility, and Oral Health in Individuals With Motor Neuron Disease.
- ClinicalTrials.gov ID
- NCT07187388
- Acronym / sponsor ID
- MND / 2025-356-NSU
- Conditions
- Amyotrophic Lateral Sclerosis (ALS), Primary Lateral Sclerosis (PLS), Motor Neuron Disease, Amyotrophic Lateral Sclerosis
- Keywords
- Amyotrophic Lateral Sclerosis, Primary Lateral Sclerosis, ALS, PLS, Motor Neuron Disease, MND, Facial Pain, jaw pain
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 10 participants (estimated)
- Lead sponsor
- Nova Southeastern UniversityUniversity, hospital or other
- Study start
- 2 Apr 2026 (actual)
- Primary completion
- 13 Aug 2026 (estimated)
- Study completion
- 13 Aug 2026 (estimated)
- First posted
- 23 Sep 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this clinical trial is to evaluate the impact of non-invasive electrical stimulation, when placed on the facial muscles can reduce facial pain and improve jaw mobility, and chewing in individuals with Amyotrophic Lateral Sclerosis (ALS) and Primary Lateral Sclerosis (PLS). The secondary goal is to evaluate the impact of non-invasive electrical stimulation on patient reported difficulty performing oral hygiene tasks in individuals with ALS and PLS. Participants will attend one in-person clinic visit and participate in one telephone interview 24 hours after the treatment. The clinic visit will include pre-intervention assessments, a single 30-minute treatment of electrical stimulation followed by post-intervention assessments.
The assessments will include a self-rating of jaw and facial pain, a range of motion test where participants will be asked to open their jaw as wide and as far to the side as possible, and a chewing efficiency test using a saltine cracker. Twenty-four hours later, participants will receive a follow-up phone call to self-rate their facial pain and report any difficulty performing oral hygiene tasks.
The treatment consists of a single 30-minute electrical stimulation session. Electrode pads will be placed on the participant's facial region, specifically over the masseter muscle belly and the TMJ area, while the participant is seated comfortably. The pads will be connected to an FDA-approved electrical stimulator, and the current will be adjusted to the participant's comfort level. Once set, the participant will remain seated for 30 minutes. At the end of the session, the stimulator will be turned off and the electrode pads removed.
Detailed description
In this prospective, cross-sectional study, individuals with ALS and PLS will participate in one in-person clinic visit, followed by a telephone interview 24 hours post-treatment. During the clinic visit, pre-intervention assessments will be conducted to evaluate facial pain, jaw range of motion (jROM), mastication efficiency, and patient-reported difficulty with oral hygiene tasks. Following these assessments, participants will receive a single 30-minute TENS treatment. The PI or Co-PI will be present throughout the intervention, monitoring for any discomfort and providing participants the option to discontinue treatment if needed using a predetermined signal.
Post-intervention assessments, identical to the pre-intervention evaluations, will then take place. The entire clinic visit is expected to take approximately 90 minutes. A brief telephone interview 24 hours after the intervention will collect subjective feedback, including patient-reported pain levels and perceived difficulty of performing oral hygiene tasks.
The primary outcome measure will be patient-reported pain, defined by the International Association for the Study of Pain "an unpleasant sensory and emotional experience associated with, or resembling that associated with, actual or potential tissue damage," localized to the jaw region and assessed using a Numeric Rating Scale (NRS). Secondary outcome measures will include jROM, the ability to chew solid foods, and participants' perceived difficulty with oral hygiene tasks, as outlined below.
Participants.
Participants will be identified and recruited during weekly ALS/PLS multidisciplinary clinic visits. The study will enroll 10 pALS/pPLS between the ages of 25 and 90.
METHODS Pre-Intervention Assessment: Estimated Time 25 minutes
- Jaw Pain Assessment: Pain levels will be assessed using the NRS scale. This scale uses a 0-10 numeric range, where 0 represents no pain and 10 represents the worst possible pain. Participants will rate their pain by choosing a number between 0 and 10 to indicate their pain intensity pre-, post-, and 24 hours post-intervention.
- Jaw Range of Motion Assessment To measure maximal incisal opening (oral opening), the TheraBite range of motion (ROM) scale will be used. The TheraBite ROM scale is a disposable tool that assists investigators to assess the distance in millimeters (mm) between the upper and lower central incisors when the patient opens their mouth as wide as possible or performs lateral jaw movements. Maximum interincisal distance (MID) and Maximal lateral jaw movement will be measured in mm both pre- and post- intervention. The participant will be instructed to open their mouth as wide as possible within a pain-free range. The TheraBite ROM Scale will be positioned between the upper and lower central incisors, and the maximum opening will be measured in millimeters (mm). The participant will be instructed to move their jaw sideways to the left and right within a pain-free range. The TheraBite ROM Scale will be used to measure the distance between the midline of the upper and lower teeth, with the values recorded in millimeters (mm). A surface EMG sensor will be positioned on the masseter muscle belly during both jROM assessments to measure muscle activity at rest, during passive stretch and during muscle activation. This will provide real-time data visualization to quantify muscle activation patterns pre- and post- intervention.
- Mastication Efficiency Assessment : Test of Mastication and Swallowing Solids (TOMASS)
The TOMASS will be utilized to assess solid bolus ingestion by quantifying masticatory efficiency, speed, and safety, providing objective measurements of mastication performance. The objective outcomes include the number of masticatory cycles and swallows per bite, and duration.
3b. Oral Transit Time (OTT)
In the event the participant cannot chew a saltine cracker, required for the TOMASS, the OTT will be utilized. The OTT is a tool to quantify how many seconds it takes a participant to consume a modified textured food item (IDDSI level 4, apple sauce) and clear bolus from oral cavity. OTT will be described using quantitative parameters from the Mann Assessment of Swallowing Ability (MASA): Score of 2 = No oral transit movement observed; Score of 4 = delay >10 seconds ; Score of 6 =delay > 5 seconds; Score of 8 = delay >1 second; Score of 10 = no OTT delay.
- Oral Hygiene - Numerical Rating Scale (NRS)
Patient-reported difficulty completing oral hygiene will be assessed using a NRS ranging from 0 (no difficulty) to 10 (significant difficulty). Participants will rate their perceived difficulty pre-intervention and 24 hours post intervention.
- TENS Intervention - 40 minutes
TENS intervention will be administered using a current-controlled TENS device that produces charge-balanced, symmetrical biphasic rectangular pulses. Participants will be seated and skin cleaned prior to applying 2 self-adhesive round surface electrodes (25mm) on each side of the face. One electrode (anode) will be placed over the masseter muscle belly, while the other (cathode) will be positioned over the TMJ. Electrode placement will be confirmed by palpation of the TMJ and Masseter. This set up will be mirrored on the opposite side. Once all 4 electrodes are in place, the TENS unit will be turned on. This is estimated to take 10 minutes.
Participants will remain seated. The TENS unit will be set to manual mode to deliver the stimulation at a frequency of 50 Hertz (Hz) and a pulse width of 200 microseconds (µseconds). Stimulation amplitudes will be gradually increased from 0 milliamps (mA) to each participant's tolerance level. Participants will be instructed to indicate when the stimulation feels "strong but comfortable." The tolerated mA level will be recorded and maintained for the full 30-minute session.
The PI or Co-PI will be present throughout the intervention, monitoring for any discomfort and providing participants the option to discontinue treatment if needed. At the end of the session, the TENS device will be powered off, electrodes will be removed, and post-intervention testing will be conducted.
- Post Intervention Assessments are identical to pre-intervention assessments and are estimated to take 25 minutes.
- 24 hour telephone interview - Estimated time - 10 minutes. The participant will be contacted 24 hours after completion of intervention and a telephone interview will be conducted. The PI or co-PI will contact the participant and collect subjective feedback, including patient reported pain levels, perceived difficulty of performing oral hygiene tasks, both rated utilizing the NRS.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Transcutaneous electrical stimulation to reduce facial pain and improve jaw ROM in ALS and PLS. | Experimental | Device: Transcutaneous Electrical Nerve Stimulation to reduce facial pain and improve jaw range of motion in ALS and PLSAll 10 participants will receive a single TENS intervention, with electrodes placed over the masseter and TMJ regions. This intervention is designed to evaluate TENS as a potential treatment for reducing facial pain and improving jaw mobility and chewing function in individuals with ALS and PLS.. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- Diagnosis of possible, probable, or definite ALS (El-Escorial Revisited) OR diagnosis of definite PLS by the treating neurologist and based on the consensus diagnostic criteria for PLS
- Subjective report of jaw pain, indicated by a NRS score of > or = 3/10.
Key exclusion criteria (8 listed)
- history of head or neck cancer
- history of CVA
- history of past facial surgery with hardware placement
- history of pacemaker
- diagnosis of significant cognitive impairment by the treating physician
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Transcutaneous Electrical Nerve Stimulation to reduce facial pain and improve jaw range of motion in ALS and PLSTENS intervention will be administered using a current-controlled TENS device that produces charge-balanced, symmetrical biphasic rectangular pulses. Participants will be seated and skin cleaned prior to applying 2 self-adhesive round surface electrodes (25mm) on each side of the face. One electrode (anode) will be placed over the masseter muscle belly, while the other (cathode) will be positioned over the TMJ. Electrode placement will be confirmed by palpation of the TMJ and Masseter. This set up will be mirrored on the opposite side. Once all 4 electrodes are in place, the TENS unit will be turned on. Participants will remain seated. The TENS unit will be set to manual mode to deliver the stimulation at a frequency of 50 Hertz (Hz) and a pulse width of 200 microseconds (µseconds). Stimulation amplitudes will be gradually increased from 0 milliamps (mA) to each participant's tolerance level. The 30 minute TENS intervention will then take place. | Device | Transcutaneous electrical stimulation to reduce facial pain and improve jaw ROM in ALS and PLS. |
Primary outcome
Numerical Rating Scale for Pain
Time frame: Baseline, immediately post-intervention and 24 hours post-intervention
0-10 numeric rating scale where participants will self rate their pain on a scale of 0-10 with 0 = no pain and 10 = worst possible pain.
3 secondary outcomes
Jaw Range of Motion (jROM) Assessment
Time frame: Baseline and immediately post-intervention
Test of Mastication and Swallowing Solids (TOMASS)
Time frame: Baseline and immediately post-intervention
Numeric Rating Scale for Oral Hygiene
Time frame: Baseline and 24 hours post intervention.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 27 May 2026.
- Background: PubMed 37823292Alizadeh A, Karagah A, Tabrizi R, Shadman L, Arjmand A, Tofangchiha M, Patini R. Effect of transcutaneous electrical nerve stimulation on pain, edema, and trismus after surgical removal of impacted third molars: a split-mouth randomized clinical trial. Med Oral Patol Oral Cir Bucal. 2024 Mar 1;29(2):e211-e218. doi: 10.4317/medoral.26193.
- Background: PubMed 32694253Zayan K, Felix ER, Galor A. Transcutaneous Electrical Nerve Stimulation for Facial Pain. Prog Neurol Surg. 2020;35:35-44. doi: 10.1159/000509620. Epub 2020 Jul 21.
- Background: PubMed 25540662Shanavas M, Chatra L, Shenai P, Rao PK, Jagathish V, Kumar SP, Naduvakkattu B. Transcutaneous electrical nerve stimulation therapy: An adjuvant pain controlling modality in TMD patients - A clinical study. Dent Res J (Isfahan). 2014 Nov;11(6):676-9.
- Link to TENS device utilizedLink provided by the sponsor.
- EMG surface sensorLink provided by the sponsor.
- Individual participant dataSharing planned: Yes. All 10 participants baseline assessments, post assessments and 24 hour interview responses will be shared.
Related trials for Amyotrophic Lateral Sclerosis (ALS)
RecruitingPhase 1/2
Study is to Assess the Safety and Tolerability of VTx-002 in Participants With ALS
Amyotrophic Lateral Sclerosis
Not yet recruiting
A Study on the Addition of Alsum30 for the Treatment of Amyotrophic Lateral Sclerosis
Amyotrophic Lateral Sclerosis (ALS), Bacillus Coagulans
Active, not recruiting
Functional Outcomes and Control Using Synchron BCI - Australia
Neurologic Disorder, Neurologic Diseases
Not yet recruitingPhase 1
Safety, Tolerability, and Pharmacodynamic Exploration of Orelabrutinib in Patients With Amyotrophic Lateral Sclerosis (ALS)
Amyotrophic Lateral Sclerosis (ALS)
Recruiting
Clinical Outcome Assessment for AT & BCI
Spinal Cord Injury, ALS (Amyotrophic Lateral Sclerosis)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Transcutaneous Electrical Nerve Stimulation to reduce facial pain and improve jaw range of motion in ALS and PLS in people with Amyotrophic Lateral Sclerosis (ALS) and Primary Lateral Sclerosis (PLS), run by Nova Southeastern University at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 27 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Kayla Chomko, PT, DPT (954-817-5730, kayla.chomko@nova.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Numerical Rating Scale for Pain (time frame: Baseline, immediately post-intervention and 24 hours post-intervention). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07187388, which also lists 3 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 May 2026.